Under deal terms, GSK will give Vesalius Therapeutics $80 million in upfront and equity payments to identify treatments for ...

Despite significant medical advancements in the oncology space, 30% of patients in the GSK/Harris Poll survey said they never ...

In a report released today, Peter Welford from Jefferies downgraded GlaxoSmithKline (GSK – Research Report) to a Hold, with a price ...

GSK’s Trelegy, a treatment for chronic obstructive pulmonary disease (COPD), aimed to address a gap in the market with its ...

The British pharma’s experience during the third quarter mirrored that of rival Pfizer, which also reported lower sales of ...

GSK has shifted towards a global marketing model ... Richardson noted that the streaming service has around nine different promotional photos for each programme – and an algorithm picks the ...

GSK (GSK) plc and Chimagen Biosciences, a privately held biotechnology company, announced an agreement for GSK to acquire ...

While generics may dominate due to cost advantages and meeting needs of a developing economy, there is a growing thrust ...

The US Food and Drug Administration has proposed to remove oral phenylephrine, widely used in cold and cough syrups.

Year to date, shares of GSK have increased 5.8% against the industry’s decline of 1.8%. Image Source: Zacks Investment ...

GlaxoSmithKline (GSK) has agreed to acquire Chimagen Biosciences’ CMG1A46, a clinical-stage therapy designed to target B cell-driven autoimmune diseases, for $300m upfront. The acquisition of ...

GlaxoSmithKline (GSK) has agreed to acquire Chimagen Biosciences’ CMG1A46, a clinical-stage therapy designed to target B cell-driven autoimmune diseases, for $300m upfront. The acquisition of CMG1A46, ...